0000000000007325

AUTHOR

Stefano Ferrari

showing 9 related works from this author

An observational, multicenter, retrospective, Italian Sarcoma Group (ISG) study of trabectedin in patients with advanced soft tissue sarcoma (STS).

2018

e23502Background: Trabectedin (T) is approved for patients (pts) with STS after failure of anthracyclines (A) and ifosfamide (I), or pts unsuited to receive AI. ISG performed a retrospective study ...

OncologyCancer Researchmedicine.medical_specialtyIfosfamidebusiness.industrySoft tissue sarcomaRetrospective cohort studymacromolecular substancesmedicine.diseasecarbohydrates (lipids)stomatognathic diseasesOncologyInternal medicineotorhinolaryngologic diseasesbacteriaMedicineObservational studyIn patientSarcomabusinessTrabectedinmedicine.drugJournal of Clinical Oncology
researchProduct

Abstract A42: miR34a: A valuable indicator of differential outcome of Ewing sarcoma patients with complex functions

2014

Abstract The identification of reliable indicators of prognosis, which may allow the stratification of patients according to different risk at diagnosis isan important aspect of translational research in Ewing sarcoma (ES). In this paper, we validated our previous evidence showing how expression of miR34a in ES tumor samples at diagnosis was signficantly associated with tumor progression (Nakatani F. J Pathol 2012). Here we analyzed a different series of speciments derived from very controlled and homogeneously treated non-metastatic ES patients, and we compared evaluation of miR34a by RT-PCR using frozen samples with that obtained by in situ hybridization on paraffin-embedded samples . The…

OncologyCancer Researchmedicine.medical_specialtyPathologyProportional hazards modelbusiness.industryCancerIn situ hybridizationmedicine.diseasePediatric cancerOncologyTumor progressionMirna expressionInternal medicinemedicineTaqManSarcomabusinessCancer Research
researchProduct

Tumor response assessment by Choi criteria in localized high-risk soft tissue sarcoma (STS) treated with chemotherapy (CT): Update at 10-year follow-…

2016

11044Background: We already reported (Cancer 2012;118:5857) on better correlation of Choi criteria (Choi) than RECIST with the outcome of pts affected by high-risk STS entering a multicentric Itali...

Cancer Researchmedicine.medical_specialtyChemotherapybusiness.industry10 year follow upSoft tissue sarcomamedicine.medical_treatmentCancerExploratory analysismedicine.diseaseTumor response030218 nuclear medicine & medical imagingSurgery03 medical and health sciences0302 clinical medicineOncologyChoi Criteria030220 oncology & carcinogenesismedicineRadiologybusinessJournal of Clinical Oncology
researchProduct

Trabectedin for patients with advanced soft tissue sarcoma: A non-interventional, retrospective, multicenter study of the italian sarcoma group

2021

The Italian Sarcoma Group performed this retrospective analysis of patients with advanced soft tissue sarcoma, pretreated with ≥1 anthracycline-based treatment, and treated with trabectedin every three weeks. Primary endpoint was to describe real-life use of trabectedin across Italy. Secondary endpoints included objective response rate (ORR) and safety. Overall, 512 patients from 20 Italian centers were evaluated. Leiomyosarcoma (37.7%)/liposarcoma (30.3%) were the most prevalent histological types (abbreviated as L-sarcoma). Patients received a median of four trabectedin cycles (range: 1–40), mostly as a second-line treatment (~60% of patients). The ORR was 13.7% superior (p &lt

0301 basic medicineLeiomyosarcomaCancer Researchmedicine.medical_specialtyDacarbazinelcsh:RC254-282GastroenterologyArticlePazopanib03 medical and health sciences0302 clinical medicineInternal medicinemedicineProgression-free survivalObservationalTrabectedinSoft tissue sarcomaPerformance statusbusiness.industrySoft tissue sarcomaReal-lifelcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.disease030104 developmental biologyOncology030220 oncology & carcinogenesisSarcomabusinessmedicine.drugTrabectedin
researchProduct

High-risk soft tissue sarcomas treated with perioperative chemotherapy: Improving prognostic classification in a randomised clinical trial

2018

Background: Patients with extremity and trunk wall soft tissue sarcoma (STS) with high malignancy grade and size >5 cm are at high-risk of death. This risk varies depending also on other patient and tumour features, including histologic subtype. This study investigated whether a prognostic nomogram can improve risk assessment of these patients. Methods: Data from high-risk STS patients enrolled in a randomised controlled trial investigating different perioperative chemotherapy regimens were analysed. Ten-year probability of overall survival (OS) and incidence of distant metastasis (DM) were computed using the prognostic nomogram Sarculator (pr-OS and inc-DM, respectively). Tumour response a…

0301 basic medicineOncologyAdultMalemedicine.medical_specialtyCancer ResearchAdolescentTumour responsePerioperative Care03 medical and health sciencesYoung Adult0302 clinical medicineInternal medicineAntineoplastic Combined Chemotherapy ProtocolsOutcome Assessment Health Caremedicinemedia_common.cataloged_instanceHumansChemotherapyEuropean unionSurvival ratemedia_commonAgedSoft tissue sarcomabusiness.industryChemotherapy; Choi criteria; Neoadjuvant; Prognosis; Soft tissue sarcoma; Tumour response; Oncology; Cancer ResearchSoft tissue sarcomaIncidence (epidemiology)SarcomaNomogramMiddle Agedmedicine.diseasePrognosisClinical trialSurvival RateNomograms030104 developmental biologyChoi criteriaOncology030220 oncology & carcinogenesisFemaleSarcomaNeoadjuvantRisk assessmentbusinessFollow-Up Studies
researchProduct

Biological indicators of prognosis in Ewing's sarcoma: An emerging role for lectin galactoside-binding soluble 3 binding protein (LGALS3BP)

2009

Starting from an experimental model that accounts for the 2 most important adverse processes to successful therapy of Ewing's sarcoma (EWS), chemoresistance and the presence of metastasis at the time of diagnosis, we defined a molecular signature of potential prognostic value. Functional annotation of differentially regulated genes revealed 3 major networks related to cell cycle, cell-to-cell interactions and cellular development. The prognostic impact of 8 genes, representative of these 3 networks, was validated in 56 EWS patients. High mRNA expression levels of HINT1, IFITM2, LGALS3BP, STOML2 and c-MYC were associated with reduced risk to death and lower risk to develop metastasis. At mul…

Cancer ResearchMice NudeEnzyme-Linked Immunosorbent AssaySarcoma EwingBiologyMetastasisMiceAntigens NeoplasmCell Line TumorBiomarkers TumorCell AdhesionmedicineAnimalsHumansGene SilencingRNA MessengerNeoplasm MetastasisGlycoproteinsOligonucleotide Array Sequence AnalysisTumor microenvironmentReverse Transcriptase Polymerase Chain ReactionCell CycleMatricellular proteinEwing's sarcomaCell cyclePrognosismedicine.diseaseImmunohistochemistryOncologyTumor progressionImmunologyGalactoside bindingCancer researchSarcomaCarrier ProteinsSignal TransductionInternational Journal of Cancer
researchProduct

The sarculator stratified prognosis of patients with high-risk soft tissue sarcomas (STS) of extremities and trunk wall treated with perioperative ch…

2017

11016 Background: Patients with extremity and trunk wall STS with high malignancy grade and size larger than 5cm are considered at high risk of death, but in fact this risk varies broadly depending on histologic subtype and size. The Sarculator, a nomogram for STS, can improve prognostic assessment of these patients. This tool was evaluated for stratifying risk of distant metastasis (DM) and overall survival (OS) in a RCT investigating perioperative chemotherapy. Methods: High-risk STS patients were randomly assigned to receive either three cycles of preoperative chemotherapy with epirubicin (120 mg/m2) and ifosfamide (9 g/m2) or the same three preoperative cycles followed by two further p…

Cancer Researchmedicine.medical_specialtybusiness.industryTrunk wallSoft tissuelaw.inventionSurgery03 medical and health sciencesMalignancy grade0302 clinical medicineOncologyRandomized controlled triallaw030220 oncology & carcinogenesisPerioperative chemotherapyMedicine030212 general & internal medicineRisk of deathbusinessJournal of Clinical Oncology
researchProduct

Expression of insulin-like growth factor system components in Ewing's sarcoma and their association with survival.

2010

Abstract Aims The role of IGF system in the pathogenesis of Ewing’s sarcoma (EWS) is well-documented. However, still little information is available about the value of IGF system components as indicators of prognosis. Understanding the clinical role for IGF system in EWS patients may be important because different subtypes of patients have distinct outcome and may require different treatment protocol. We evaluated the expression of insulin-like growth factor (IGF)-receptor (IGF-IR), insulin receptor (IR), IGF-I and some major intracellular mediators (IRS1, p-ERK) in specimens from EWS patients with primary localised untreated tumours. Patients and methods 290 samples were used for immunohis…

MaleCancer Researchmedicine.medical_specialtyAdolescentmedicine.medical_treatmentEnzyme-Linked Immunosorbent AssaySarcoma EwingPathogenesisInsulin-like growth factorInternal medicinemedicineHumansInsulin-Like Growth Factor IReceptorChildbiologyReverse Transcriptase Polymerase Chain ReactionEwing's sarcomaCancermedicine.diseasePrognosisImmunohistochemistryIRS1Gene Expression Regulation NeoplasticInsulin receptorEndocrinologyTreatment OutcomeOncologybiology.proteinCancer researchDisease ProgressionFemaleSarcomaEuropean journal of cancer (Oxford, England : 1990)
researchProduct

The Nasal Epithelium as a Factory for Systemic Protein Delivery

2002

We have previously shown that recombinant Sendai virus (SeV) produces efficient in vivo airway epithelial gene transfer. The ability to produce therapeutic levels of circulating proteins following noninvasive gene transfer would have widespread clinical application. Here, we compared nose, lung, and skeletal muscle for the ability to produce circulating levels of the secreted mouse antiinflammatory cytokine interleukin-10 (IL10) following SeV-mediated gene transfer. High levels of serum IL10 were obtained from each site with a potency order of lung > nose > muscle for a given viral titer. Serum levels from each site were within the likely required range for anti-inflammatory effects. The co…

virusesGenetic enhancementmedicine.medical_treatmentMucous membrane of noseSendai virus03 medical and health sciences0302 clinical medicineIn vivoDrug DiscoverymedicineGeneticsAnimalsHumansMuscle SkeletalLungMolecular BiologyNose030304 developmental biologyPharmacology0303 health sciencesLungbiologyGene Transfer TechniquesSkeletal musclerespiratory systembiology.organism_classificationSendai virus3. Good healthInterleukin-10Nasal Mucosamedicine.anatomical_structureCytokine030220 oncology & carcinogenesisImmunologyCOS CellsMolecular MedicineHeLa CellsMolecular Therapy
researchProduct